X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
ADCOCK INGRAM
Jun-14
ALEMBIC PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs664357-   
Low Rs412258-   
Sales per share (Unadj.) Rs208.7106.3-  
Earnings per share (Unadj.) Rs31.0-26.8-  
Cash flow per share (Unadj.) Rs37.1-22.2-  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.283.5-  
Shares outstanding (eoy) m188.52168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.9 89.1%   
Avg P/E ratio x17.4-11.5 -151.2%  
P/CF ratio (eoy) x14.5-13.9 -104.7%  
Price / Book Value ratio x3.73.7 101.2%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,46151,922 195.4%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m7,4673,259 229.1%   
Avg. sales/employee Rs ThNM4,180.1-  
Avg. wages/employee Rs ThNM759.1-  
Avg. net profit/employee Rs ThNM-1,053.3-  
INCOME DATA
Net Sales Rs m39,34717,945 219.3%  
Other income Rs m94126 74.6%   
Total revenues Rs m39,44118,071 218.3%   
Gross profit Rs m8,736-3,110 -280.9%  
Depreciation Rs m1,152775 148.8%   
Interest Rs m184486 37.9%   
Profit before tax Rs m7,493-4,245 -176.5%   
Minority Interest Rs m11-12 -91.3%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568265 591.0%   
Profit after tax Rs m5,844-4,522 -129.2%  
Gross profit margin %22.2-17.3 -128.1%  
Effective tax rate %20.9-6.2 -334.8%   
Net profit margin %14.9-25.2 -58.9%  
BALANCE SHEET DATA
Current assets Rs m19,57713,143 149.0%   
Current liabilities Rs m14,8967,395 201.4%   
Net working cap to sales %11.932.0 37.1%  
Current ratio x1.31.8 73.9%  
Inventory Days Days90111 80.9%  
Debtors Days Days45124 36.6%  
Net fixed assets Rs m27,0977,661 353.7%   
Share capital Rs m37783 452.5%   
"Free" reserves Rs m26,8110-   
Net worth Rs m27,18814,085 193.0%   
Long term debt Rs m4,9934,950 100.9%   
Total assets Rs m47,77826,608 179.6%  
Interest coverage x41.7-7.7 -539.3%   
Debt to equity ratio x0.20.4 52.3%  
Sales to assets ratio x0.80.7 122.1%   
Return on assets %12.6-15.2 -83.2%  
Return on equity %21.5-32.1 -67.0%  
Return on capital %23.6-19.8 -119.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m13,3880-   
CASH FLOW
From Operations Rs m8,1201,532 530.1%  
From Investments Rs m-7,556-470 1,606.6%  
From Financial Activity Rs m5904,492 13.1%  
Net Cashflow Rs m1,1535,554 20.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.93 Rs / ZAR

Compare ALEMBIC PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: STRIDES PHARMA SCIENCE  JUBILANT LIFE SCIENCES  FDC LTD.  NOVARTIS  SUN PHARMA  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views On News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati (Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance (The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 17, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS